Haleon Plc - ADR logo

Haleon Plc - ADR (H6D)

Market Closed
12 Dec, 20:00
XBER XBER
8. 10
-0.05
-0.61%
- Market Cap
28.96 P/E Ratio
0.07% Div Yield
0 Volume
0.45 Eps
8.15
Previous Close
Day Range
8.1 8.25
Year Range
7.45 10.2
Want to track H6D and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 73 days

Summary

H6D closed Friday lower at €8.1, a decrease of 0.61% from Thursday's close, completing a monthly increase of 2.53% or €0.2. Over the past 12 months, H6D stock lost -10.99%.
H6D pays dividends to its shareholders, with the most recent payment made on Sep 18, 2025. The next estimated payment will be in In 4 days on Dec 18, 2025 for a total of €0.059.
The last earnings report, released on Jul 31, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 25, 2026.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NYSE (USD).

H6D Chart

Haleon not out of the woods yet, with analysts saying questions still remain

Haleon not out of the woods yet, with analysts saying questions still remain

Haleon PLC's (LSE:HLN, NYSE:HLN) third-quarter numbers were in line with expectations and the outlook was maintained, but analysts at Barclays flagged that the toothpaste, painkiller and vitamin maker is not yet out of the woods.  Organic sales growth (OSG) of 3.4% for the quarter was in line with the average analyst forecast, helped by better volumes, though the Oral Health arm saw growth short of the City consensus.

Proactiveinvestors | 1 month ago
Haleon plc (HLN) Q3 2025 Sales Call Transcript

Haleon plc (HLN) Q3 2025 Sales Call Transcript

Haleon plc ( HLN ) Q3 2025 Sales Call October 30, 2025 5:00 AM EDT Company Participants Joanne Russell - Head of Investor Relations Dawn Allen - CFO & Director Conference Call Participants Guillaume Gerard Delmas - UBS Investment Bank, Research Division Olivier Nicolai David Hayes - Jefferies LLC, Research Division Jeremy Fialko - HSBC Global Investment Research Celine Pannuti - JPMorgan Chase & Co, Research Division Karel Zoete - Kepler Cheuvreux, Research Division Mikheil Omanadze - BNP Paribas Exane, Research Division Tom Sykes - Deutsche Bank AG, Research Division Warren Ackerman - Barclays Bank PLC, Research Division Edward Lewis - Rothschild & Co Redburn, Research Division Presentation Operator Good morning. Thank you for attending today's Haleon 2025 Quarter 3 Trading Statement.

Seekingalpha | 1 month ago
Haleon outlook held steady as organic growth improves in third quarter

Haleon outlook held steady as organic growth improves in third quarter

Haleon PLC (LSE:HLN, NYSE:HLN) delivered a slight improvement in organic revenue growth of 3.4% in the third quarter and maintained its full-year guidance. The maker of Sensodyne, Panadol and Centrum saw top-line expansion pick up from 3.0% in the second quarter.

Proactiveinvestors | 1 month ago

Haleon Plc - ADR (H6D) FAQ

What is the stock price today?

The current price is €8.10.

On which exchange is it traded?

Haleon Plc - ADR is listed on NYSE.

What is its stock symbol?

The ticker symbol is H6D.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.07%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 25, 2026.

Has Haleon Plc - ADR ever had a stock split?

No, there has never been a stock split.

Haleon Plc - ADR Profile

Specialty Retail Industry
Consumer Discretionary Sector
Brian James McNamara CEO
XBER Exchange
US4055521003 ISIN
GB Country
24,561 Employees
15 Aug 2025 Last Dividend
- Last Split
22 Jul 2022 IPO Date

Overview

Haleon plc, a leading entity in consumer healthcare, operates on a global scale with a focus on research, development, manufacturing, and marketing of a wide range of consumer healthcare solutions. With its subsidiaries, Haleon’s operational reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Initially known as DRVW 2022 plc, the company underwent a rebranding to Haleon plc in February 2022. Founded in the year 1715, and based in Weybridge, United Kingdom, Haleon has established a significant presence in the consumer healthcare industry by offering products that cater to oral health, vitamins, minerals, supplements, and over-the-counter medicinal needs.

Products and Services

Oral Health Products: Haleon’s oral health portfolio includes toothpastes, mouth washes, and denture care products, marketed under reputable brands such as Sensodyne for sensitive teeth, Polident for denture care, Parodontax for gum health, and Biotene for dry mouth relief. These products are tailored to meet diverse oral health needs of consumers across the globe.

Vitamins, Minerals, and Supplements: Addressing nutritional gaps, Haleon offers an extensive range of vitamins, minerals, and supplements. Products under the Centrum brand provide comprehensive multivitamins for adults and children, Emergen-C offers vitamin C and other essential nutrients for immune support, and Caltrate is tailored for bone health, with its high calcium and vitamin D content.

Over-the-Counter Medicinal Products: Haleon’s commitment to alleviating common health issues extends to its over-the-counter product line, including:

  • Nasal Drops and Respiratory Solutions: Under brands like Otrivine, Theraflu, and Flonase, Haleon provides relief for nasal congestion, cold, flu, and allergies, catering to respiratory health needs.
  • Anti-Inflammatory and Pain Relief: With products like Voltaren for topical pain relief, Panadol for general pain relief, and Advil for inflammation and pain, Haleon delivers solutions that aid in managing discomfort effectively.
  • Antacids and Antihistamines: For digestive health issues, Haleon offers TUMS and ENO as antacids, and Fenistil, an antihistamine, to address allergic reactions and related discomforts.

Contact Information

Address: Building 5
Phone: 44 1932 822000